Morrison Patrick J, Atkinson A Brew
Regional Medical Genetics Centre, Belfast City Hospital HSC Trust, Belfast BT9 7AB, United Kingdom.
Oncologist. 2009 Jun;14(6):571-7. doi: 10.1634/theoncologist.2009-0046. Epub 2009 May 22.
Familial thyroid cancer is rare, accounting for <10% of thyroid cancer cases. Activating germline point mutations in the RET proto-oncogene are associated with multiple endocrine neoplasia types 2A, 2B, and familial medullary thyroid cancer (FMTC)-around 3% of thyroid cancer cases. Familial papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) have been identified as a distinct group of familial thyroid cancers. Sporadic nonmedullary thyroid cancer (NMTC) accounts for approximately 90% of all thyroid cancers-about 6% of NMTCs are familial (FNMTC). Although multiple endocrine neoplasia types 2A and 2B and FMTC are well characterized, very little is known about the genetic predisposition to PTC and FTC. In this paper, the genetic types of FMTC and FNMTC are reviewed and the clinical features and screening are outlined.
家族性甲状腺癌较为罕见,占甲状腺癌病例的比例不到10%。RET原癌基因中的激活种系点突变与2A、2B型多发性内分泌肿瘤以及家族性甲状腺髓样癌(FMTC)相关——约占甲状腺癌病例的3%。家族性乳头状甲状腺癌(PTC)和滤泡状甲状腺癌(FTC)已被确定为一组独特的家族性甲状腺癌。散发性非髓样甲状腺癌(NMTC)约占所有甲状腺癌的90%——约6%的NMTC为家族性(FNMTC)。尽管2A和2B型多发性内分泌肿瘤以及FMTC已得到充分表征,但对于PTC和FTC的遗传易感性知之甚少。本文对FMTC和FNMTC的基因类型进行了综述,并概述了其临床特征和筛查情况。